
|Videos|July 30, 2020
ASRS 2020: What Aviceda’s lead candidate AVD-104 may mean for dry AMD
Author(s)Alex Delaney-Gesing
Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.
Advertisement
Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD, in an interview with Sheryl Stevenson, Modern Retina's® group editorial director, during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
ONL Therapeutics randomizes first European patient in phase 2 GA trial of Xelafaslatide
2
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
3
Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion
4
Ophthalmic drug shortages more frequent, longer lasting than average
5


































